PPSB as first choice treatment in the reversal of oral anticoagulant therapy.
In the treatment of reversal of oral anticoagulant therapy, a number of treatment modalities is available and depends on the severity of the clinical situation and the degree of the coagulopathy. FFP and PPSB (PCC) are commonly used in the treatment and/or in combination with cessation of oral anticoagulant therapy and administration of Vitamin K. The double viral inactivated plasma product PPSB-SD is the first choice treatment in this indication because of the relatively constant, high concentrated level of the Vitamin K dependent coagulation factors II, VII, IX and X, compared to FFP.
Strengers
P F W
PF
Paul.Strengers@caf-dcf.redcross.be
Drenth
J C
JC
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D019934:International Normalized Ratio; D010949:Plasma; D014812:Vitamin K / Q000008:administration & dosage
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D014812:Vitamin K; C025667:prothrombin complex concentrates